Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Number of shares and votes in Calliditas Therapeutics

Calliditas reorganizes its management team

Exercise of over-allotment option and end of the stabilization period

Number of shares and votes in Calliditas Therapeutics

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market

Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market

Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States

Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas publicly files registration statement with SEC for a proposed initial public offering in the United States

Interim Report Q1, 2020

Calliditas Therapeutics’ 2019 Annual Report published

Calliditas appoints new Chief Medical Officer

Calliditas moves its Annual General Meeting 2020 to June 25

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)

Year-End Report 2019

Notice of extraordinary general meeting of Calliditas Therapeutics AB (publ)

Calliditas submits draft registration statement for the listing of ADSs in the U.S.

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2020